CV Science

denis angoulvant Pr Denis Angoulvant, MD, PhD - Cardiology & Cardiovascular Physiology

Course and current status

Course

Medical school at UFR Lariboisière Saint-Louis Paris 7 Denis Diderot University.

Clinical training at University Hospital of Lyon, France and Claude Bernard University Lyon 1, Lyon, France. MD obtained in 2002.

Research training at Inserm U886 (Pr Ovize) Lyon, France and Toronto General Hospital - University Health Network (Dr R Weisel and Dr R-K Li) 2003-2005, Toronto, Ontario, Canada. PhD obtained in 2008.

Albert Sezary award of the French National Academy of Medicine.

Research fellowship "Lavoisier" from the French ministry of foreign affairs

Research fellowship and PhD fellowship from the Fédération Française de Cardiologie.

Research fellowship from the Fondation pour la Recherche Médicale 2012.

Research grant from the fédération Française de Cardiologie 2012.

Research grant from the Agence de la Biomédecine 2013.

Research fellowship from the Fédération Française de Cardiologie 2013, 2015, 2017.

Current position

Dean of the Faculty of medicine - University of Tours, Tours, France.

Professor of cardiovascular medicine (Cardiac Intensive Care Unit & Interventional Cardiology) & Head of Cardiology department at Tours University Hospital, Hôpital Trousseau, and University of Tours, Tours, France.

Senior researcher and deputy director of UMR Inserm 1327 ISCHEMIA Membrane Signalling and Inflammation in reperfusion injuries at University of Tours 

Scientific summary

In basic science, my research interests focus on immuno inflammatory responses to cardiovascular stress. Our research group is conducting preclinical studies investigating the mechanisms and effects of immuno inflammatory responses modulation at the time of acute myocardial infarction and heart graft transplantation. We are also working on regulation of inflammation and immune signalling for acute and chronic myocardial diseases : Damage Associated Molecular Patterns, purinergic receptors, TLR, stem cell mobilisation, cytokine activation, extracellular matrix remodeling, dendritic cells modulation, myocardial cell injuries.

I am collaborating with the MABImprove research group (http://mabimprove.univ-tours.fr/?lang=en) specialized in the development and evaluation of monoclonal antibodies for the treatment of numerous diseases including cardiovascular diseases.

Our research group is involved in the FHU "SUPORT" an Inter University Hospital collaboration aiming at improving solid organ graft survival.

In clinical research, I am the director of the cardiovascular intensive care & interventional cardiology research group of our university hospital.

Our group is actively recruiting patients in clinical studies on ischemic and pharmacologic post conditioning to prevent  acute myocardial reperfusion infarction. We are also participating in clinical trials and registries focused on atherosclerosis, pulmonary embolism, anti thrompbotic agents and myocarditis. Because of our involvment in the MABImprove group we are actively recruiting patients in clinical trials evaluating Therapeutics Monoclonal Antibodies in cardiovascular diseases such as anti PCSK9 MABs. We are also members of the FACT (French Alliance for Clinical Trials) network.

Editorial activities :

Member of the editorial board of Archives of Cardiovascular Diseases

Past member of the editorial board of the Journal of Molecular and Cellular Cardiology.

Medical and scientific societies :

Fellow of the European Society of Cardiology (FESC) member of the working group on "Cellular Biology of the Heart"

Past President of the GRRC (Cardiovascular Research Branch of the French Society of Cardiology)

Past vice president of the Fédération Française de Cardiologie (FFC), past president of the scientific committee and president of the regional association of the  Fédération Française de Cardiologie for the Loire Valley, 

Elected member of the board of the French Society of Cardiology (SFC) coordinator of the research promotion committee

Past expert for the French National Research Agency  (ANR) and The High Council for Evaluation of Research and Higher Education (Hcéres)

H index: 44 (Web of Science)

X id: @AngoulvantD